Symptom assessment by means of the COPD-Assessment Test (CAT) in patients treated with Roflumilast – a 6 month non-interventional study

Background: Symptom improvement is important in patients with chronic obstructive pulmonary disease (COPD). The purpose of this prospective, single-arm non-interventional study was to investigate the effects of the anti-inflammatory PDE-4 inhibitor roflumilast 500 µg once daily on symptoms of COPD in routine clinical care. For this purpose, the COPD Assessment Test™ (CAT) was used. Methods: 3597 patients (male: 65.2%; mean age: 65.5 ± 9.9 years; mean BMI 27.3 ± 5.7 kg/m2) were enrolled in 739 study centres in Germany in the year 2011 and treated with roflumilast 500 µg once daily for up to 6 months (intention-to…